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Objectives: Treatment targets in inflammatory bowel disease (IBD) move
away from controlling symptoms towards complete recovery of the intesti-
nal mucosa. Currently, the most frequently used noninvasive surrogate
marker of mucosal healing is a faecal calprotectin concentration in the
target range. This study tested if there was a relation between time-to-reach
target calprotectin and first flare.
Methods: We prospectively included new-onset IBD patients ages 17 and
younger in a cloud-based registry (FastForwardCare) and followed them for
at least 52 weeks. They were treated according to Dutch national guidelines
that advocate a step-up approach. Time-to-reach target was defined as the
first calprotectin measurement below 250mg/g after the start of induction
therapy. Time-to-first flare was the time from the first calprotectin
measurement below 250mg/g until reappearance of symptoms with
calprotectin values above 250mg/g.
Results: We included 76 patients (luminal Crohn disease [CD] 43);
ulcerative colitis [UC] 33). Median age at diagnosis was, respectively
14.5 and 14.1 years. Median time-to-reach target calprotectin was
37 weeks in CD and 11 weeks in UC patients (Log-rank test, P¼ 0.001).
Once the calprotectin target was reached, time-to-first flare was significantly
longer in CD than in UC patients (Log-rank test, P¼ 0.001). CD patients
with time-to-reach target calprotectin 12 weeks after conventional
induction therapy (ie, exclusive enteral nutrition or steroids) had a more
favorable disease course in the first year than those with time-to-reach target
calprotectin >12 weeks (Log-rank test, P¼ 0.057). In UC patients, time-to-
reach target calprotectin 12 weeks is not associated with a favorable
disease course in the first year.
Conclusions: The findings of this prospective registry suggest that a quick
response to conventional therapy predicts a favorable disease course in new-
onset paediatric CD, but not in UC. The concept ‘‘time-to-reach target
calprotectin level’’ rationalizes the indefinite term ‘‘response to treatment’’
and is well suited for studying treatment effectiveness in real-worldpractices.
Key Words: inflammatory bowel diseases, personalized medicine,Factor agents.I nflammatory bowel diseases (IBD), including Crohn disease (CD)and ulcerative colitis (UC), develop during childhood or adoles-
cence in approximately 10% of patients (1). Paediatric-onset IBD is
associated with more extensive disease, higher disease activity, and a
more complicated course than adult-onset IBD (2,3). The focus of
modern-day IBD management is moving away from controlling
symptoms (or clinical remission) towards reaching and maintaining
complete recovery of the intestinal mucosa, constituting both endo-healing (mucosal healing, MH) (4). MH is
atient outcomes and is said to reduce the risk
). MH is ideally evaluated by endoscopy with
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biopsies, but repeated endoscopic procedures are poorly tolerated.
Currently, the most frequently used noninvasive surrogate marker of
MH is faecal calprotectin (FC). FC levels below 250mg/g correlate
wellwithMH,FC levels rise quickly above this target threshold in case
of disease flare andFC levels rapidly fall with successful treatment (6).
In the past decade, the approach to treating children with
luminal CD and UC has been classically described as ‘‘step up,’’
whereas only few exceptional conditions at diagnosis warranted
early and continuing use of anti-tumour necrosis factor (TNF)
agents, including patients with perianal fistulizing disease, growth
failure, or extra-intestinal manifestations (7). Although we
acknowledge the importance of recognizing patients who are most
at risk of developing a complicated disease course at diagnosis, we
argue that risk stratification should not stop there. The identification
of high- and low-risk patients for complicated disease should
probably continue after diagnosis and extend into the first year
of treatment.
For that purpose, we prospectively followed newly diag-
nosed children with luminal CD or UC who were initially treated
with conventional induction therapy and evaluated whether there
was a relation between time-to-reach target calprotectin and
first flare.
METHODS
Study Design and Setting
This was a noninterventional, observational study in which
patient data were prospectively entered in an online registry, from
diagnosis onwards.We used the cloud-based FastForwardCare (FFC)
platform, which is especially designed to capture patients’ records in
an easy and comprehensive way (https://www.fastforwardcare.nl/).
JPGN  Volume 69, Number 4, October 2019FFC is a health network inwhich care providers, researchers, patients
and families learn together to improve the care for childrenwith IBD.
With effect from January 2015 the University Medical Center
FIGURE 1. Flarometer strategy. Algorithm with advice on treatment an
Heida et al (11).
www.jpgn.orgGroningen (UMCG) has started the collection of patient data. More
IBD treatment centerswill be invited to join this health network in the
coming years. The FFC platform has options for writing medical
summaries, creation of medical letters and building a research
database without the drawback of double data entry. Care providers
can trace back database information to their individual patients; other
users only have access to anonymized data.
Health checks and data collection were done at structured time
points, but not at fixed intervals.We used phenotype-specific clinical
composite scores (Paediatric Ulcerative Colitis Activity Index
[PUCAI] (8) and the shortened Paediatric Crohn Disease Activity
Index [shPCDAI]) (9,10). Stool samples were sent to the department
of laboratory sciences of the UMCG and were analysed with fCAL
ELISA (BU¨HLMANN Laboratories AG, Scho¨nenbuch,
Switzerland). The results of both the symptom score and the calpro-
tectin stool test cumulated in a relapse risk stratification (Flarometer
score) that has been described previously (11,12). In brief, a patient
who was in the low-risk stratum (symptom score below 10 and
calprotectin below 250mg/g) was reassured and advised to retest
in 3months. A symptomatic patient with a calprotectin concentration
above 250mg/g was considered to have active disease and required
immediate adjustment of therapy and retesting after 1 month. In the
intermediate-risk stratum, a test interval of 1 month was advised
before progressing to a treatment decision (Fig. 1).
The ethical committee of the UMCG reviewed the study
protocol and waived the need for informed consent because of the
anonymous and noninterventional approach of the registry.
Participants
We used the clinical data of patients up to the age of 17 years
Time-to-reach Target Calprotectin in Newly Diagnosed IBDwho were newly diagnosed with luminal CD or UC between
January 2015 and July 2017. National treatment guidelines pro-
vided uniformity in treatment among physicians (13). Patients with
d the timing of re-measurement. Reproduced with permission from
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active luminal CD were treated with steroids (to a maximum of
40mg/day) and gradual dose tapering, or with exclusive enteral
nutrition (EEN) for 6 weeks. Patients with active UC were treated
with steroids and aminosalicylate dose escalation. Maintenance
therapy was started at the same time as induction therapy and in
CD, this included standardized doses of mercaptopurine (1–
1.5mg  kg1  day1), azathioprine (2–2.5mg  kg1  day1) or
methotrexate (15mg m2 week1), while in UC this included
aminosalicylate monotherapy (60-80mg  kg1  day1) or combi-
nation therapy with azathioprine. Antitumor necrosis factor (TNF)
therapy was indicated after failure of conventional therapy.
Data Collection
At diagnosis, patient demographics, disease characteristics,
and detailed information on diagnostic work-up (including baseline
laboratory values, endoscopic examination, histological features,
and small bowel imaging) were recorded online in the FFC registry.
Stool specimen were collected at home and sent to the hospital
laboratory before each face-to-face patient-doctor encounter, as
previously described (14). During health checks, all of the following
variables were entered in the FFC registry: present treatment,
clinical signs and symptoms, follow-up of laboratory values and
faecal calprotectin, PUCAI or shPCDAI, a final conclusion (remis-
sion, clinical improvement, imminent relapse, relapse), and any
treatment adjustments.
Definitions and Outcome Measures
IBD was diagnosed according to the Revised Porto criteria
(15) and disease phenotype, location, and behavior were described
according to the Paris classification (16). Faecal calprotectin con-
centrations below 250mg/g were considered as a proxy for mucosal
healing (17–20). Time-to-reach target was defined as the first
calprotectin measurement below 250mg/g after the start of induc-
tion therapy (Figure, Supplemental Digital Content 1, http://
links.lww.com/MPG/B688). Time-to-first flare, which was our pri-
mary outcome measure, was defined as the time from the first
calprotectin measurement below 250mg/g until reappearance of
symptoms with calprotectin values above 250mg/g (ie, having a
flarometer score in the high-risk stratum). Growth delay was
defined as height-for-age less than or equal to 2 SD.
Statistical Analyses
This was an exploratory study, with neither formal hypothe-
sis testing nor sample size calculation. Data analyses were per-
formed using IBM SPSS version 23.0 for Apple Mac (IBM
Corporation, Armonk, NY). Baseline demographics and disease
characteristics were evaluated using descriptive statistics, including
median and interquartile ranges (IQR: 25th percentile, 75th per-
centile) for continuous variables. For discrete variables, we calcu-
lated the 95% confidence interval in OpenEpi, Version 3. Time-to-
event data were analysed by Kaplan-Meier and log-rank tests. P
values <0.05 were considered statistically significant. Graphs were
constructed with GraphPad Prism version 7 for MacBook (Graph-
Pad Software, San Diego, CA). Patients with fistulizing CD were
excluded from the survival analysis.
RESULTS
Haisma et alPatient Demographics
A total of 76 newly diagnosed children with IBD were
identified between January 2015 to July 2017. Fifty-seven percentage
468(43/76) had luminal CD and 43% (33/76) had UC. Table 1 shows the
patient characteristics. Patients included in the FFC registry were
diagnosed at a median age of 14.5 years (IQR 11.9–16.3) and 14.1
years (IQR 12–15.8), for CD and UC, respectively. Fifty-three
percentage (23/43) of CD patients was female, compared with
49% (16/33) of UC patients. Growth delay at diagnosis was reported
in 17% (7/41) ofCDpatients and in 6% (2/32) ofUCpatients.Median
follow-up of patients was 67 weeks (IQR 54–86).
Diagnostic Work-up
Abnormal Laboratory Tests at Diagnosis
Blood examination at diagnosis showed abnormal values of
C-reactive protein (CRP) and/or erythrocyte sedimentation rate
(ESR) in 67% (29/43) of CD patients and in 45% (15/33) of UC
patients. Forty-eight percentage (21/43) of CD patients and 42%
(14/33) of UC patients presented with anaemia. All but 1 patient had
faecal calprotectin levels out of the normal range (>250mg/g). One
UC patient with continuous inflammation from rectum to sigmoid
had a calprotectin level of 220mg/g at diagnosis. This patient was
excluded from Kaplan-Meier analysis for having reached the event
of interest at baseline.
Endoscopic and Histological Features at Diagnosis
Disease location and behavior are shown in Table 1. Five
patients, who were ultimately diagnosed with UC, had histologic
features of focally enhanced gastritis. Small bowel imaging by
magnetic resonance enterography (MRE) was performed in 10
patients with indefinite colonic inflammation to distinguish CD
from UC. Abnormalities suggestive for CD were seen in 6 patients,
whereas the remaining 4 patients with normal MRE findings were
initially diagnosed as IBD-unclassified. Follow-up colonoscopies
confirmed a diagnosis of CD in 3 patients and UC in 1 patient.
Initial Induction and Maintenance Therapy
Figure, Supplemental Digital Content 2 (http://links.lww.-
com/MPG/B688) shows the flow of patients through the first year
postdiagnosis. Forty-nine percentage (21/43) of patients diagnosed
with luminal CD were initially treated with EEN to induce remis-
sion and 51% (22/43) with steroids. Seventy percentage (30/43) of
CD patients reached the treatment target during the observation
period (whether or not after switch or step-up) and were included in
the analysis of the primary outcome measure (time-to-first flare).
Eighty-four percentage (27/32) of UC patients were induced
with oral steroids in combination with aminosalicylates, whereas
13% (4/32) of patients, in particular, those with ulcerative proctitis,
were induced with topical aminosalicylates. One patient with UC
was initially misdiagnosed as luminal CD and put on EEN. The final
diagnosis was adjusted after colonoscopy was repeated. Ultimately
94% (30/32) of UC patients reached the treatment target during the
observation period (whether or not after switch or step-up) and were
included in the analysis of the primary outcome measure.
First choice immunomodulator for CD patients was azathio-
prine in 93 percentage (40/43) of cases. Eighty-four percentage (27/
32) of the UC patients were on oral aminosalicylate maintenance
therapy, in 85% (23/27) of cases in combination with azathioprine.
Disease Course in the First Year Postdiagnosis
Time-to-reach Target Calprotectin Levels
JPGN  Volume 69, Number 4, October 2019(<250mg/g)
Figure 2 shows the time-to-reach target calprotectin levels
(<250mg/g) in the study population in the first year postdiagnosis.
www.jpgn.org
both curves follow a parallel track. The patients that ultimately
TABLE 1. Patient characteristics at diagnosis
CD (n¼ 43) UC (n¼ 33)
Demographic features
Median age in years (IQR) 14.5 (11.9–16.3) 14.1 (12–15.8)
Female sex 54% 49%
Family history of IBD
First degree relatives 6% (2–17) 10% (4–26)
Second degree relatives 18% (10–31) 15% (7–31)
IBD-related comorbidity
Joint inflammation 20% (11–34) 14% (5–31)
Eye manifestations 4% (1–14) -
Skin manifestations 4% (1–14) -
Growth delay

17% (9–31) 6% (2–20)
Laboratory markers
CRP, >10 mg/L 49% (35–63) 24% (13–41)
ESR, >20 mm/h 61% (46–74) 39% (25–56)
Hb, <2SD (sex and age adjustedy) 49% (35–63) 42% (27–59)
Stool Calprotectin, >250mg/g 100% (93–100) 97% (85–99)
Disease location (according to Paris Classification)
L1: Distal 1/3 ileum 19% (10–33)
L2: colonic 42% (28–57)
L3: ileocolonic 44% (30–59)
L4a: upper disease proximal to ligament of Treitz

5% (1–15)
L4b: upper disease distal to ligament of Treitz and proximal to distal 1/3 ileum

23% (13–38)
L4ab: upper disease above and below the ligament of Treitz 37% (24–52)
E1: ulcerative proctitis 24% (13–41)
E2: left-sided UC (distal to splenic flexure) 9% (3–24)
E3: extensive (distal to hepatic flexure) –
E4: pancolitis (proximal to hepatic flexure) 67% (50–80)
Disease behaviorz
B1: nonstricturing, nonpenetrating 84% (70–92)
B2: structuring 7% (2-19
B3: penetrating 5% (1–15)
B2B3: both penetrating and stricturing disease 5% (1–15)
p: perianal disease 35% (22–50)
Values are percentages (95% confidence interval) unless otherwise stated.
Growth delay was defined as height versus age 2 SD.
yWe used age- and sex-adjusted cut points for low haemoglobin blood levels (Hb). Cut-offs were 7.1 g/L for boys and girls younger than 13 years, 8.1 g/L for
boys 13 to 17 years, and 7.4 g/L for girls between 13 and 17 years (36).
The
JPGN  Volume 69, Number 4, October 2019 Time-to-reach Target Calprotectin in Newly Diagnosed IBDNineteen percentage (8/43) of patients with luminal CD reached the
target within 12 weeks after diagnosis. Another 42% (18/43)
reached the target between 12 and 52 weeks postdiagnosis, for
which 14 patients required a step-up to anti-TNFs. Forty percentage
(17/43) had not reached the treatment target after 52 weeks of
follow-up. Another 4 patients with CD reached the calprotectin
target concentration after 52 weeks of follow-up.
Among patients with UC, 53% (17/32) reached the target
within 12 weeks after diagnosis. Another 31% (10/32) reached the
target between 12 and 52 weeks postdiagnosis, for which 1 patient
needed step-up to anti-TNFs. Thirteen percentage (5/32) had not
reached the treatment target at the end of 52 weeks’ follow-up.
Another 3 UC patients reached the calprotectin target concentration
after 52 weeks of follow-up.
A significant larger proportion of patients with UC reached
the calprotectin target in the first year compared with patients
with CD, and also at a faster pace. The median time-to-reach
zMagnetic resonance enterography was performed in 10 of 43 CD patients.
an underestimation.target calprotectin levels was, respectively, 11 and 37 weeks
(Log-rank test, P¼ 0.001). The slopes for UC and CD patients in
Figure 2 indicate that the difference in time-to-reach target
www.jpgn.orgcalprotectin is in the first 12 weeks postdiagnosis. Thereafter,
reported proportion of patients with penetrating or structuring disease may bereached the calprotectin target served as the study population to
evaluate time-to-first flare.
Time-to-first Flare After Reaching the Calprotectin
Target
Figure 3 shows the time-to-first flare after reaching the
calprotectin target. Patients with CD who had reached the treat-
ment target remained in remission for a significantly longer time
than patients with UC (Log-rank test, P¼ 0.001). Figure 4 shows
that new-onset CD patients who reached the target calprotectin
level within 12 weeks were more likely to have a favorable
disease course, than CD patients who reached the target
calprotectin after 12 weeks (Log-rank test, P¼ 0.057). In UC
patients there was no association between the pace of reaching
the target calprotectin and favorable disease course (Log-rank
test, P¼ 0.547).
469
FIGURE 2. Kaplan-Meier plot demonstrating time-to-reach target calprotectin (<250mg/g) in the first year postdiagnosis. Patients with
ulcerative colitis (solid line) and Crohn disease (dotted line) were treated according to the Dutch step-up approach. One patient with UC had
m t
Haisma et al JPGN  Volume 69, Number 4, October 2019In both CD and UC patients, 1-year outcomes including time-
to-reach target calprotectin and time-to-first flare were similar
regardless of initial choice of induction therapy, although our study
was not powered to address this question (Table, Supplemental
Digital Content 3, http://links.lww.com/MPG/B688).
Figure, Supplemental Digital Content 4 (http://links.lww.
com/MPG/B688) gives an overview of changes in faecal calpro-
tectin from baseline to the moment of reaching the target range
(DFC#) and from the last result in range to the first out-of-range
result (DFC ). The median DFC was 2095 (interquartile range,
a faecal calprotectin value of 220mg/g at diagnosis was excluded fro
baseline." #
IQR3000 to 1281)mg/g. The medianDFC"was 860 (interquartile
range, IQR 557–1922) ug/g. Ninety-five percentage (72/76) of IBD
patients in our cohort had FC concentrations over 500mg/g at
FIGURE 3. Kaplan-Meier plot demonstrating time-to-first relapse, defined
until reintroduction of induction therapy (whether or not step-up). Patien
Crohn disease (dotted line).
470baseline. Eighty-eight percent (53/60) of patients had FC concen-
trations below 200mg/g when the target range was reached. Simi-
larly, in those who flared during the observation period, FC
concentrations were below 200mg/g shortly before the flare in
92% (23/25) of cases. The first out-of-range measurement was over
500mg/g in 96% (24/25) of cases.
DISCUSSION
Key Findings
he Kaplan-Meier analysis for having reached the event of interest atWe quantified time-to-reach target calprotectin levels and its
relation with first flare in patients with new-onset paediatric IBD.
The data were drawn from the FastForwardCare Registry. We
as the time from the first calprotectin measurement below 250mg/g
ts with ulcerative colitis (solid line) are compared with patients with
www.jpgn.org
FIGURE 4. Kaplan-Meier plot demonstrating time-to-first relapse, defined as the time from the first calprotectin measurement below 250mg/g
until reintroduction of induction therapy (whether or not step-up) in 30 patients with Crohn disease. Patients who reached the target calprotectin
the
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<250mg/g) at a faster pace than patients with CD, but they also
experienced a first flare sooner than patients with CD. Additionally,
we observed that CD patients with time-to-reach target calprotectin
12weeks after conventional induction therapy (ie, exclusive enteral
nutrition or steroids) had a more favorable disease course in the first
year than those with time-to-reach target calprotectin>12 weeks. In
UC patients, time-to-reach target calprotectin 12 weeks was not
associated with a favorable disease course in the first year.
Comparison With Existing Literature
Several research groups have identified factors at disease
diagnosis that warranted early and ongoing use of anti-TNF agents,
including perianal fistulizing disease, presence of strictures or
penetrating disease in CD, and extensive disease (pancolitis) or
extraintestinal manifestations in UC (21–26).
In addition, we have now shown that the absence of response
to conventional induction therapy (with EEN or steroids), rational-
ized in a failure to reach target calprotectin levels within 12 weeks
from initiation, facilitates selection of patients with CD that may
require an accelerated step-up therapy. A recently published Pan-
European study among patients with new-onset paediatric CD also
stressed the prognostic power of calprotectin values at week 12
of induction therapy, and showed that response to induction
therapy has more impact than baseline disease severity or
inflammation (27).
Faecal Calprotectin Cut-point
within 12 weeks (solid line) are compared with patients who reachedThe discussion about the best calprotectin cut-point for
mucosal healing is on-going, and the debate is blurred by the
www.jpgn.orgintended purpose of this stool test. In many articles, the use of a
single calprotectin measurement is compared with a reference test
(such as endoscopy or MRE) (28), whereas we use calprotectin at
every health check (ie, periodically) and now adjust our therapy
plans based on the trend in calprotectin results. By analogy with the
most frequently used monitoring test in medicine—the measure-
ment of blood pressure—the variability over time makes a single
measurement a poor monitoring test. Fecal calprotectin becomes a
good monitoring test when therapy adjustment is based on a series
of measurements.
Choosing a cut-point that is considerably lower than 250mg/
g used in this project (eg, 150mg/g) will definitely improve the
specificity of the calprotectin test. At the same time, this may be
detrimental to the outcome of patients with calprotectin results
between 150 and 250mg/g, who may need to undergo pointless
changes of therapy that lead to quick exhaustion of the therapeutic
arsenal. Evaluation of the best calprotectin cut-point should,
therefore, not be limited to the reporting of receiver operating
characteristic (ROC) curves, as is done in many publications (28),
but must also include the monitoring strategy, definitions of action
thresholds, and the actions to be taken if any of the thresholds
is reached.
Limitations
Although there is an imminent danger of over-interpretation
of results in an observational study, our results offer insight into the
short-term outcomes of new-onset paediatric IBD patients, where
double-blind randomized controlled trials are unlikely to occur. The
target calprotectin beyond 12 weeks (dotted line).University Medical Center in Groningen was the first center to start
capturing data in the FastForwardCare prospective registry. We
realize that single-center studies are unlikely to have sufficient
471
power to draw reliable conclusions, especially when evaluating the
effect of treatment choices on time-to-event analyses, and we,
therefore, aim to encourage more paediatric IBD treatment centers
to join the registry in the upcoming years.
Implications for Paediatric Practice and Further
Research
Several trials have shown that early use of anti-TNF agents is
associated with improved outcomes and fewer complications in
adult as well as in paediatric patients with CD (25,29–34). This
does not necessarily mean that every new-onset IBD patient will
profit from the early institution of anti-TNF induction treatment. A
significant proportion of patients with IBD have a relatively favor-
able disease course, with long time-to-first flare and low risk of
complications. We are the first to have shown that a time-to-reach
target calprotectin level within 12 weeks is predictive for a favor-
able disease course in the short run in patients with new-onset CD,
but not in patients with UC.
Given that calprotectin is a cytosolic protein, particularly,
abundant in neutrophils, these results are not unexpected. Influx of
neutrophils in the epitheliumor in the intestinal lumen are known to
increase the amount of calprotectin in the gut lumen (35). ln UC,
the inflammation is confined to the mucosal layer, whereas in CD
also the deeper layers may be affected. We postulate that time-to-
elimination of neutrophils (in other words time-to-histologic heal-
ing) takes longer in CD, and this may be reflected in the longer
time-to-reach target calprotectin levels. CD patients with a swift
normalization of calprotectin values by induction therapy may
have had a less deep type of inflammation, but we were unable
to prove this in the present study, because of absence of follow-
up biopsies.
CONCLUSIONS
With the use of a prospective registry, we have shown that
reaching calprotectin levels <250mg/g within 12 weeks of the
initiation of induction therapy, facilitates recognition of new-onset
CD patients with a favorable disease course, but this does not apply
to new-onset UC patients. CD patients who fail to reach target
calprotectin levels within 12 weeks after conventional induction
therapy may be entitled to step-up to anti-TNF agents.
REFERENCES
1. Ghione S, Sarter H, Fumery M, et al. Dramatic increase in incidence
of ulcerative colitis and Crohn’s disease (1988-2011): a population-
based study of French adolescents. Am J Gastroenterol 2018;113:
265–72.
2. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of
pediatric Crohn’s disease: a population-based cohort study. Gastroen-
terology 2008;135:1106–13.
3. Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn’s disease:
comparison between childhood- and adult-onset disease. InflammBowel
Dis 2010;16:953–61.
4. Peyrin-Biroulet L, Bressenot A, KampmanW. Histologic remission: the
ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol
Hepatol 2014;12:929.e2–34.e2.
5. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic
Targets in Inflammatory Bowel Disease (STRIDE): determining ther-
apeutic goals for treat-to-target. Am JGastroenterol 2015;110:1324–38.
6. Zittan E, Kelly OB, Kirsch R, et al. Low fecal calprotectin correlates
Haisma et alwith histological remission and mucosal healing in ulcerative colitis and
colonic Crohn’s disease. Inflamm Bowel Dis 2016;22:623–30.
7. Ruemmele FM, Veres G, Kolho KL, et al., European Crohn’s and
Colitis Organisation; European Society of Pediatric Gastroenterology,
472Hepatology and Nutrition. Consensus guidelines of ECCO/ESPGHAN
on the medical management of pediatric Crohn’s disease. J Crohns
Colitis 2014;8:1179–207.
8. Turner D, Otley AR, Mack D, et al. Development, validation, and
evaluation of a pediatric ulcerative colitis activity index: a prospective
multicenter study. Gastroenterology 2007;133:423–32.
9. Hyams JS, Ferry GD,Mandel FS, et al. Development and validation of a
pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr
1991;12:439–47.
10. Kappelman MD, Crandall WV, Colletti RB, et al. Short pediatric
Crohn’s disease activity index for quality improvement and observa-
tional research. Inflamm Bowel Dis 2011;17:112–7.
11. Heida A, Dijkstra A, Muller Kobold A, et al. Efficacy of home
telemonitoring versus conventional follow-up: a randomized controlled
trial among teenagers with inflammatory bowel disease. J Crohns
Colitis 2018;12:432–41.
12. Dijkstra A, Heida A, van Rheenen PF. Exploring the challenges of
implementing a web-based telemonitoring strategy for teenagers with
inflammatory bowel disease: empirical case study. J Med Internet Res
2019;21:e11761.
13. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for
Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of
known IBD, detection of complications. J Crohns Colitis 2019;13:144–
64.
14. Haisma SM, van Rheenen PF, Wagenmakers L, et al. Calprotectin
instability may lead to undertreatment in children with IBD. Arch
Dis Child 2019. DOI: 10.1136/archdischild-2018-316584. [Epub ahead
of print].
15. Levine YY, Koletzko J, Turner D. ESPGHAN revised Porto criteria for
the diagnosis of inflammatory bowel disease in children and adoles-
cents. Zhonghua Er Ke Za Zhi 2016;54:728–32.
16. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the
Montreal classification for inflammatory bowel disease: the Paris clas-
sification. Inflamm Bowel Dis 2011;17:1314–21.
17. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control
management on Crohn’s disease (CALM): a multicentre, randomised,
controlled phase 3 trial. Lancet 2018;390:2779–89.
18. Kristensen V, Roseth A, Ahmad T, et al. Fecal calprotectin: a reliable
predictor of mucosal healing after treatment for active ulcerative colitis.
Gastroenterol Res Pract 2017;2017:2098293.
19. Jauregui-Amezaga A, Lopez-Ceron M, Aceituno M, et al. Accuracy of
advanced endoscopy and fecal calprotectin for prediction of relapse in
ulcerative colitis: a prospective study. Inflamm Bowel Dis 2014;20:
1187–93.
20. Zhulina Y, Cao Y, Amcoff K, et al. The prognostic significance of faecal
calprotectin in patients with inactive inflammatory bowel disease.
Aliment Pharmacol Ther 2016;44:495–504.
21. Guizzetti L, Zou G, Khanna R, et al. Development of clinical prediction
models for surgery and complications in Crohn’s Disease. J Crohns
Colitis 2018;12:167–77.
22. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn’s
disease. Gastroenterology 2006;130:650–6.
23. Khanna R, Jairath V, Feagan BG. The evolution of treatment paradigms
in Crohn’s Disease: beyond better drugs. Gastroenterol Clin North Am
2017;46:661–77.
24. Van Assche G, Dignass A, Panes J, et al., European Crohn’s and Colitis
Organisation (ECCO). The second European evidence-based Consensus
on the diagnosis and management of Crohn’s disease: definitions and
diagnosis. J Crohns Colitis 2010;4:7–27.
25. Kugathasan S, Denson LA, Walters TD, et al. Prediction of compli-
cated disease course for children newly diagnosed with Crohn’s
disease: a multicentre inception cohort study. Lancet 2017;389:
1710–8.
26. Yarur AJ, Strobel SG, Deshpande AR, et al. Predictors of aggres-
sive inflammatory bowel disease. Gastroenterol Hepatol 2011;7:
652–9.
JPGN  Volume 69, Number 4, October 201927. Ziv-Baran T, Hussey S, Sladek M, et al. Response to treatment is more
important than disease severity at diagnosis for prediction of early
relapse in new-onset paediatric Crohn’s disease. Aliment Pharmacol
Ther 2018;48:1242–50.
www.jpgn.org
JPGN  Volume 69, Number 4, October 2019 Time-to-reach Target Calprotectin in Newly Diagnosed IBD28. Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin,
and stool lactoferrin for detection of endoscopic activity in symptomatic
inflammatory bowel disease patients: a systematic review and meta-
analysis. Am J Gastroenterol 2015;110:802–19.
29. D’Haens G, Baert F, van Assche G, et al., Belgian Inflammatory Bowel
Disease Research Group; North-Holland Gut Club. Early combined
immunosuppression or conventional management in patients with new-
ly diagnosed Crohn’s disease: an open randomised trial. Lancet
2008;371:660–7.
30. Walters TD, Kim MO, Denson LA, et al., PRO-KIIDS Research Group.
Increased effectiveness of early therapy with anti-tumor necrosis factor-
alpha vs an immunomodulator in children with Crohn’s disease. Gas-
troenterology 2014;146:383–91.
31. Khanna R, Bressler B, Levesque BG, et al., REACT Study Investigators.
Early combined immunosuppression for the management of Crohn’s
disease (REACT): a cluster randomised controlled trial. Lancet
2015;386:1825–34.www.jpgn.org32. Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the
placebo-controlled CHARM trial: increased remission rates through
3 years for adalimumab-treated patients with early Crohn’s disease. J
Crohns Colitis 2013;7:213–21.
33. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine,
or combination therapy for Crohn’s disease. N Engl J Med 2010;
362:1383–95.
34. Jongsma MME, Cozijnsen MA, van Pieterson M, et al. Top-down
infliximab superior to step-up in children with moderate-to-severe
Crohn’s disease - a multicenter randomized controlled trial. J Pediatr
Gastroenterol Nutr 2019:40–168S1.
35. Magro F, Lopes J, Borralho P, et al., Portuguese IBD Study Group
(GEDII). Comparison of different histological indexes in the assessment
of UC activity and their accuracy regarding endoscopic outcomes and
faecal calprotectin levels. Gut 2018;68:594–603.
36. Nathan DG, Orkin SH, LockAT, et al. Nathan and Oski’s Hematology of
Infancy and Childhood. Philadelphia: Saunders; 2003.473
